0001104659-23-119546.txt : 20231117 0001104659-23-119546.hdr.sgml : 20231117 20231117163605 ACCESSION NUMBER: 0001104659-23-119546 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231113 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231117 DATE AS OF CHANGE: 20231117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVAVAX INC CENTRAL INDEX KEY: 0001000694 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222816046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26770 FILM NUMBER: 231419368 BUSINESS ADDRESS: STREET 1: 700 QUINCE ORCHARD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 240-268-2000 MAIL ADDRESS: STREET 1: 700 QUINCE ORCHARD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 8-K 1 tm2331053d1_8k.htm FORM 8-K
false 0001000694 0001000694 2023-11-13 2023-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 13, 2023

 

 

NOVAVAX, INC.

(Exact name of registrant as specified in charter)  

 

 

Delaware   0-26770   22-2816046

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

700 Quince Orchard Road

Gaithersburg, Maryland 20878

(Address of Principal Executive Offices, including Zip Code)

 

(240) 268-2000

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

  

Title of each class   Trading
Symbol(s)
  Name of each exchange on which
registered
Common Stock, Par Value $0.01 per share   NVAX   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b), (c) and (e)

 

Appointment of John Trizzino as President and Chief Operating Officer

 

On November 17, 2023, the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) approved the appointment of John J. Trizzino to the newly created role of President and Chief Operating Officer of the Company, effective November 20, 2023. In connection with this appointment, Mr. Trizzino’s annual base salary will be increased by $50,000 to $570,000. Otherwise, Mr. Trizzino will continue to be compensated in accordance with the terms of his Employment Agreement with the Company, dated February 26, 2014, as amended.

 

Retirement of John A. Herrmann III

 

On November 13, 2023, John A. Herrmann III informed the Company of his intention to retire from his role as Chief Legal Officer and Corporate Secretary, effective December 8, 2023. Mr. Herrmann will continue to provide consulting services to the Company following his retirement, as further described below.

 

In connection with his retirement, the Company and Mr. Herrmann entered into a consulting agreement (the “Consulting Agreement”) on November [17], 2023, pursuant to which Mr. Herrmann will serve as the Company’s Senior Advisor for legal matters and will provide consulting and advisory services to the Company following his retirement until December 10, 2024 (subject to earlier termination or extension, the “consulting period”). The Consulting Agreement provides that Mr. Herrmann will receive a consulting fee (the “Consulting Fee”) of $44,167 per month and, subject to the recommendation of the Chief Executive Officer and approval of the Compensation Committee of the Board, a one-time incentive payment in respect of the 2023 bonus he would have received if his employment had continued, pro-rated to reflect the portion of the year during which Mr. Herrmann served as our Chief Legal Officer and Secretary. The equity awards previously granted to Mr. Herrmann will continue to vest based on his continued service during the consulting period in accordance with their existing terms, and any stock options that remain outstanding and unexercised as of the last day of the consulting period will remain exercisable for a period of 90 days following the end of the consulting period (collectively, the “Equity Treatment”).

 

Under the terms of the Consulting Agreement, if Mr. Herrmann’s service is terminated by the Company without cause or if Mr. Herrmann terminates his service with the Company for good reason (each, as defined in the Consulting Agreement) prior to the end of the consulting period (but not, for the avoidance of doubt, during any extension of the consulting period following December 10, 2024), the Company will pay Mr. Herrmann, in a lump sum payment, the amount of unpaid Consulting Fees, if any, that would otherwise be payable from the date of termination through December 10, 2024 and his outstanding equity awards will remain eligible for the Equity Treatment through such date.

 

The post-termination period applicable to Mr. Herrmann’s current non-competition, as modified by the Consulting Agreement, and non-solicitation covenants will commence upon his retirement with the Company.

 

The foregoing description of the material terms of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement, a copy of which will be filed with the SEC as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

A press release regarding the appointment of Mr. Trizzino as President and Chief Operating Officer, the retirement of Mr. Herrmann, and the appointment of Mark Casey as Chief Legal Officer and Secretary is furnished as Exhibit 99.1 to this Current Report on Form 8-K

 

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release, dated November 17, 2023.
104   Cover Page Interactive Data File (formatted as Inline XBRL).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NOVAVAX, INC.
     
     
Date: November 17, 2023 By: /s/ James P. Kelly
  Name: James P. Kelly
  Title: Executive Vice President, Chief Financial Officer and Treasurer

 

 

 

EX-99.1 2 tm2331053d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Press Release  

 

 

Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities

 

·New organizational structure for executive leadership team designed to facilitate a leaner and more focused approach to annual execution of business plans
·John Trizzino appointed to new Chief Operating Officer role
·Mark Casey to join as Chief Legal Officer and Corporate Secretary

 

GAITHERSBURG, Md., November 17, 2023 – Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the company’s scale and structure announced last week.

 

John Trizzino will take on the newly created role of President and Chief Operating Officer for the Company. In this role, Mr. Trizzino will lead the commercial; chemistry, manufacturing and controls or CMC; and regulatory functions for the Company. He will continue to serve on the Company’s executive leadership team. 

 

Current Chief Legal Officer and Corporate Secretary John Herrmann will retire effective December 8, and Mark Casey will join the Company as his successor effective December 11. Mark will also serve on the Company’s executive leadership team.

 

“As we announced last week, we are keenly focused on effectively delivering our COVID-19 product to market and evolving Novavax’s scale and structure to position the company for future success. In his new role as Chief Operating Officer, John Trizzino will focus on all aspects of successful product delivery, both for the 2023-2024 vaccination season and beyond. His deep knowledge of the company and our processes will help to facilitate the transition to a more streamlined and efficient operating model,” said John C. Jacobs, President and Chief Executive Officer, Novavax. “As Chief Legal Officer for nearly 14 years, John Herrmann helped transition Novavax from a clinical development organization to a global commercial vaccine company during a worldwide pandemic. We are incredibly grateful for his leadership, and I am delighted that John has agreed to serve as an advisor to me and the Company for the next year. His successor, Mark Casey, brings more than 30 years of experience to Novavax, and we look forward to the next chapter with him at the helm of our legal team.”

 

Mr. Trizzino has broad experience in publicly held companies and over 25 years in the vaccines market. During his 12 years with Novavax, Mr. Trizzino most recently served as Executive Vice President, Chief Commercial Officer and Chief Business Officer, and has also held the roles of Chief Financial Officer, Senior Vice President of Commercial Operations and Senior Vice President of Business Development. Previously, Mr. Trizzino served as Chief Executive Officer of Immunovaccine, successfully leading the company into clinical development within the infectious disease and cancer immunotherapy business, and has also held leadership roles at MedImmune, LLC (now AstraZeneca), ID Biomedical and Henry Schein, Inc. Mr. Trizzino holds a Bachelor of Science from Long Island University and a Master of Business Administration from New York University, Stern School of Business.

 

  2

 

 

Mr. Casey has decades of experience in the life sciences sector and most recently served as Chief Legal Officer and Corporate Secretary at Bryn Pharma. He previously served as Chief Legal Officer, Corporate Secretary and Executive Chairman of the Board - Specialty Generics at Mallinckrodt Pharmaceuticals where he led business turnaround inclusive of enhancing profitability through rationalization of the R&D portfolio, identifying applications for underutilized manufacturing capacity and executive-level changes. Earlier in his career, Mr. Casey held executive leadership roles at Idera Pharmaceuticals and Hologic and held roles of increasing responsibility at Boston Scientific and EMC Corp. Mr. Casey holds a Bachelor of Science from Syracuse University and a Juris Doctor from Suffolk University Law School.

  

About Novavax 

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world’s most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information. 

 

Forward-Looking Statements 

Statements herein relating to the future of Novavax, its operating plans and prospects, including the continued evolution of the Company’s scale and structure, and the effective delivery of its updated XBB version of its Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in obtaining regulatory authorization for its product candidates, including its updated XBB version of its COVID-19 vaccine in time for the fall 2023 vaccination season or for future COVID-19 variant strain changes; challenges or delays in clinical trials; manufacturing, distribution or export delays or challenges; Novavax’s exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; challenges in obtaining commercial adoption of our updated protein-based non-mRNA XBB COVID-19 vaccine, NVX-CoV2373 or any COVID-19 variant strain-containing formulation; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. 

 

Contacts: 

Investors 

Erika Schultz 

240-268-2022 

ir@novavax.com 

  

Media 

Ali Chartan 

240-720-7804 

media@novavax.com

 

  3

 

GRAPHIC 3 tm2331053d1_img001.jpg GRAPHIC begin 644 tm2331053d1_img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH ***0D*,D@ =S0 M%8VK>);+1[ZUM+A)6>XQAD&0H) MP,_C5%?%DK>-&T Z;*$'2?/^SG./2ME0J-TA[PVB:G9M-I4^]&'!9?J M.U7"7)JM_P C&I3]I[LOAZKO?\2O#I5I%;VL4D2SFV4".24 L,=\U(RJ-S('&X#U(J9.3U M9<81BK114O\ 0[#4-,O+!X%CBNUQ*8@$+>^1WKE+NTU?P59:7I?A73&O;9Y2 M;B23YCDD=<8V@^O08KMK>[MKL,;:XBF"\$QN&Q^5!NK?[1]F-Q$)R,B/>-V/ MIUK2%24='JNP.">JT9*"#T(..*6N5\/Z=I_A34IM-DUF2>\U&0SQQ3M\V!GI M^OUQ755$XJ+TV*3NM0HHHJ!A7D_QG@-U?^%(!*T1DNG02)]Y]>L5Y[\ M2M"U36-5\,2Z?9R7"6MVSSLA'R+E.3D^Q_*M:+M-,F>QC^/_ (=:!I'@NXU' M389(+ZS*RBX\UF=SN&=Q)Z\YSZT_QGK>IW7A#PKI=O=-%<:WY23S#AMN%SS[ MDUV7C_3[O5?!&IV5C T]S*@"1KC).X>M8>M^"[S7? &BVT+_ &36--BBE@WG MI(JC*G\NOJ*TC.Z3D^I+6]@N?@_X7.B/:6\$D=VJ$I>&1BX?'#'L1GMBN9T9 M+OX@_!Z^L+LM/J&FR'[/,QRSE1N4?4@E?QK6?Q%\2[FQ.F)X62&]9?+-^91L M!Z%P.@]>I^E=9X&\*+X0\.1V#2++<.QEGD P&<]A[#I0Y2C'WG=WT"R;T.4A M\?[?@Y_:NX_VBB?80O\ %YWW0&9;"- MQ'.;A6_M74 MRTD;-SL4MM3\,G/T J;Q]X U35O&=O#K/\ L!?#BZM!;L5MKM9=J[.HS[<^WI4W@KP_XGL/B-JNKZ_;[S<6 MW,\1!C+':=B]^!Q^%4V[2N]!*VFA1\3PS_"WQ2/$FDHKZ1J+%+FRW;0),$\? MCDCTY%;_ ,-= DDAE\7ZLZSZMJN9%;KY,9Z*/3H/H !56#POJ/C?Q=<:KXJL M)+?2K53%8Z?*P^;(Y=L'\?KCTJ?P5I6O^#M?NM DM9KOP_(QDM+L$'R2><-S MG']>>]*3O&U]02UOT.OU(Z=;ZKIUQ<6!FO'?R8)TAWF+/4D_PCG]:UJ@EEG6 MZ@CCM]\+[O,DW@>7@<<=\U/7,WHC4****0!1110 4444 %%%% !1110 4444 M -DW[#Y94/VW=*4$$D9&1U%+59X! 9[F"/=.Z],_>(Z5$FUJOZ]"DD]"S16; M)JJV5A'<:@C1,[;=H&?Q_*K$FI6<-Q;P27"++<#,2GJU3&M"77M^.Q;HS[=_ MPW+5(2%&20![U5CU&VDU*73U0Q??.%'S @'Y3SW MJU)/8EP EX-101.SCH 4 nvax-20231113.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 nvax-20231113_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 nvax-20231113_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 13, 2023
Entity File Number 0-26770
Entity Registrant Name NOVAVAX, INC.
Entity Central Index Key 0001000694
Entity Tax Identification Number 22-2816046
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 700 Quince Orchard Road
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20878
City Area Code 240
Local Phone Number 268-2000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.01 per share
Trading Symbol NVAX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2331053d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001000694 2023-11-13 2023-11-13 iso4217:USD shares iso4217:USD shares false 0001000694 8-K 2023-11-13 NOVAVAX, INC. DE 0-26770 22-2816046 700 Quince Orchard Road Gaithersburg MD 20878 240 268-2000 false false false false Common Stock, Par Value $0.01 per share NVAX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " 4X0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "" MA'%7)!Z;HJT #X 0 &@ @ &N$0 >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " ""A'%799!YDAD! #/ P $P M @ &3$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" #=$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://novavax.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nvax-20231113.xsd nvax-20231113_lab.xml nvax-20231113_pre.xml tm2331053d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2331053d1_8k.htm": { "nsprefix": "nvax", "nsuri": "http://novavax.com/20231113", "dts": { "schema": { "local": [ "nvax-20231113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nvax-20231113_lab.xml" ] }, "presentationLink": { "local": [ "nvax-20231113_pre.xml" ] }, "inline": { "local": [ "tm2331053d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://novavax.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2331053d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2331053d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-119546-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-119546-xbrl.zip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